Article Published In Oncotarget Explores Cellular Rejuvenation Diets

Oncotarget is a successful online medical journal which was established in 2010. It is a peer-reviewed and open access journal which is published by Impact Journals. The co-founders and editors-in-chief of this journal are Dr. Mikhail Blagosklonny and Andrei V. Gudkov, both researchers and professors at the Roswell Park Cancer Institute in Buffalo, New York.

Initially, Oncotarget was focused on the medical field of Oncology only. Its success in this field has led to Oncotarget also publishing articles from a large number of other medical fields such as Neurology, Metabolism, Cell Biology, Endocrinology, and many others as well. The articles that are published in Oncotarget are often cited in other research papers. The journal is peer reviewed and is published by Impact Journals.

Starting to publish research articles from fields other than Oncology helped to fulfill one of the primary missions of Oncotarget which is to break down the walls between different medical specialties. The end result that Oncotarget wants to contribute towards is the ultimate end of life with diseases. They support both basic and clinical science in support of this goal.

One research paper that was recently published in Oncotarget was about how nutrition plays a role in cellular rejuvenation. Research has shown that restricting the amount of dietary energy a person eats leads to them having an extended lifespan. It also slows down aging processes. By eating less people can lead a longer and better life. This can be done through periodic fasting as has been shown in research involving mice. The mice that were sedentary and obese were much more likely to experience a premature death in these experiments. Oncotarget is also available on Dove Press.

This new research was conducted by Patricia Huebbe, Gerald Rimbach, and Anke Schloesser who are colleagues at the University of Kiel in Germany. They used nutritional geometry approaches in order to determine that the diets that lead to longevity are not the diets that lead to the best reproductive success. Their conclusion was that by eating a diet that leads to longevity one will need to do so at the expense of growth and reproduction.

Tempus and the Startup Genius of Eric Lefkofsky

Eric Lefkofsky went to law school at the University of Michigan Law and is currently worth $165 billion. After college, in 1994, he bought Brandon Apparel with his business partner Bradley Keywell, but they lost money on it. Afterwards, they they started an internet business, Starbelly, that they eventually sold for a whopping $240 million. Mr Lefkofsky has currently co-founded Tempus, Groupon, Uptake Technologies, Mediaocean, Echo Global Logistics, and InnerWorkings. He and his wife, Liz, have also started a charitable foundation, the Lefkofsky Family Foundation, where they focus on arts and culture, human rights, education, and health.

Barb Darrow has written an article, “This Is What’s Missing in the Data-Centric Approach to Cancer”, at Fortune.com about Eric Lefkofsky, and his newest startup, Tempus. Lefkofsky believes doctors are missing useful information they could be using to treat their patients. When it takes a 90 days and a grant to research the result of past patient treatments, time is wasted. People respond differently to treatments, and it is Lefkofsky’s goal to put all the patient data together, so that doctors can compare notes and make better decisions regarding the treatment of their cancer patients.

The company Tempus, is used to collect patient information and take all of the personal information out, so that the data for treatment results can be shared with researchers and doctors. When all of the data is shared, it will become much clearer as to what treatments work better on different types of people. When Lefkofsky’s wife became ill with breast cancer, he realized the oncologist did not have relevant data to analyze the outcome of her cancer treatments, so he started Tempus. Along with the doctors, he wants companies, like CRISPR, that personalize vaccines and treat various diseases through gene research, to use the data collected and better their research.